JPET Celsis microsomes equal better data

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 12, 2004; DOI: 10.1124/jpet.103.061192


0022-3565/04/3091-137-145$20.00
JPET 309:137-145, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.061192v1
jpet.103.061192v2
309/1/137    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leblais, V.
Right arrow Articles by Muller, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leblais, V.
Right arrow Articles by Muller, B.

CARDIOVASCULAR

Role of {alpha}-Adrenergic Receptors in the Effect of the {beta}-Adrenergic Receptor Ligands, CGP 12177, Bupranolol, and SR 59230A, on the Contraction of Rat Intrapulmonary Artery

Véronique Leblais, Fabrice Pourageaud, M. Dolores Ivorra, Christelle Guibert, Roger Marthan, and Bernard Muller

Institut National de la Santé et de la Recherche Médicale EMI-0356, Université Victor Segalen Bordeaux 2, Laboratoire de Pharmacologie de la Faculté de Pharmacie (V.L., F.P., B.M.) and Laboratoire de Physiologie Cellulaire Respiratoire (C.G., R.M.), Bordeaux, France; and Departament de Farmacologia, Facultat de Farmacia, Universitat de Valencia, Valencia, Spain (M.D.I.)

This study investigates the effect of the aryloxypropanolamines 4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimidazol-2-one (CGP 12177), bupranolol, and 3-(2-ethylphenoxy)-1[(1S)-1,2,3,4-tetrahydronaphth-1-ylamino]-(2S)-2-propanol oxalate (SR 59230A) [commonly used as {beta}3- and/or atypical {beta}-adrenergic receptors ({beta}-AR) ligands] on the contractile function of rat intralobar pulmonary artery. Affinities of {beta}-AR ligands for {alpha}1-adrenergic receptors ({alpha}1-AR) were also evaluated using [3H]prazosin binding competition experiments performed in rat cortical membranes. In intralobar pulmonary artery, CGP 12177 did not modify the basal tone, but antagonized the contraction induced by the {alpha}1-AR agonist phenylephrine (PHE). In arteries precontracted with PHE, CGP 12177 elicited relaxation, whereas in those precontracted with prostaglandin F2{alpha} (PGF2{alpha}), it further enhanced contraction. CGP 12177 induced an increase in intracellular calcium concentration in pressurized arteries loaded with Fura PE-3 and precontracted with PGF2{alpha}. In PGF2{alpha} precontracted arteries, phentolamine (an {alpha}-AR antagonist) and phenoxybenzamine (an irreversible {alpha}-AR antagonist) antagonized the contractile responses to PHE and CGP 12177. Both responses were also decreased by bupranolol and SR 59230A. Specific [3H]prazosin binding was displaced by CGP 12177, bupranolol, and SR 59230A with pKi values of 5.2, 5.7, and 6.6, respectively. In contrast, (±)-(R*,R*)-[4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]phenoxy]acetic acid sodium (BRL 37344) and disodium 5-[(2R)-2-([(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino)propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL 316243) (nonaryloxypropanolamines {beta}3-AR agonists) displayed very low affinity for [3H]prazosin binding sites (pKi values below 4). These data suggest that CGP 12177 exhibits partial agonist properties for {alpha}1-AR in rat pulmonary artery. They also show that bupranolol and SR 59230A exert an {alpha}1-AR antagonist effect. As a consequence, these aryloxypropanolamine compounds should be used with caution when investigating the role of {beta}3- and atypical {beta}-AR in the regulation of vascular tone.


Received October 7, 2003; accepted December 19, 2003.

Address correspondence to: Dr. Véronique Leblais, Laboratoire de Pharmacologie de la Faculté de Pharmacie, INSERM EMI-0356, Université Victor Segalen Bordeaux 2—Casier 83, 146 rue Léo Saignat, 33076 Bordeaux cedex, France. E-mail: veronique.leblais{at}phcodyn.u-bordeaux2.fr




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
V. Leblais, E. Delannoy, F. Fresquet, H. Begueret, N. Bellance, S. Banquet, C. Allieres, L. Leroux, C. Desgranges, A. Gadeau, et al.
{beta}-adrenergic relaxation in pulmonary arteries: preservation of the endothelial nitric oxide-dependent {beta}2 component in pulmonary hypertension
Cardiovasc Res, January 1, 2008; 77(1): 202 - 210.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.